MedTrace Logo

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

NCT05583409 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-10-17

No results posted yet for this study

Summary

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib

Conditions

  • Stage IV Non-small Cell Lung Cancer

Interventions

RADIATION

SBRT+Osimertinib

Received SBRT after three months of Osimertinib treatment

DRUG

Osimertinib 80 MG

Osimertinib 80mg, po, Qd

Sponsors & Collaborators

  • Hubei Cancer Hospital

    collaborator OTHER

  • Li Zhang

    lead OTHER

Principal Investigators

  • Li Zhang, MD,PhD · Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05583409 on ClinicalTrials.gov